| Hanger Prosthetics & Orthotics West | |
| 3030 Matlock Rd, Ste 108, Arlington, Texas 76015 | |
| (817) 467-9977 |
| Name | Hanger Prosthetics & Orthotics West |
|---|---|
| Organization Name | Hanger Prosthetics & Orthotics West Inc |
| Location | 3030 Matlock Rd, Ste 108, Arlington, Texas 76015 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (817) 467-9977 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Contrary to clinical recommendations, older women with early stage breast cancer may want to undergo radiation after lumpectomy to help ensure that they will not need a mastectomy in the future. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings indicate that current thinking on the risks and benefits of radiation for early stage breast cancer in older women may be inaccurate.
In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.
Targeted Genetics Corporation (the "Company") today announced that it has received a written notice from the staff of The NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on Thursday, January 21, 2010, and that NASDAQ would initiate procedures to delist the Company's common stock.
Cancer Research UK-funded scientists have discovered that linking a molecule which initiates antibody production,to a 'saboteur' molecule, triggers the immune system to selectively destroy faulty cells. These findings published in Blood, could potentially be used to selectively destroy tumour cells while ignoring healthy cells.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.
› Verified 2 days ago
| NPI Number | 1689748576 |
| Organization Name | HANGER PROSTHETICS & ORTHOTICS WEST INC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 3030 Matlock Rd, Suite 108, Arlington, TX 76015 |
| Phone Number | 817-467-9977 |
News Archive
Contrary to clinical recommendations, older women with early stage breast cancer may want to undergo radiation after lumpectomy to help ensure that they will not need a mastectomy in the future. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings indicate that current thinking on the risks and benefits of radiation for early stage breast cancer in older women may be inaccurate.
In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.
Targeted Genetics Corporation (the "Company") today announced that it has received a written notice from the staff of The NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on Thursday, January 21, 2010, and that NASDAQ would initiate procedures to delist the Company's common stock.
Cancer Research UK-funded scientists have discovered that linking a molecule which initiates antibody production,to a 'saboteur' molecule, triggers the immune system to selectively destroy faulty cells. These findings published in Blood, could potentially be used to selectively destroy tumour cells while ignoring healthy cells.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.
› Verified 2 days ago
News Archive
Contrary to clinical recommendations, older women with early stage breast cancer may want to undergo radiation after lumpectomy to help ensure that they will not need a mastectomy in the future. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The findings indicate that current thinking on the risks and benefits of radiation for early stage breast cancer in older women may be inaccurate.
In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.
Targeted Genetics Corporation (the "Company") today announced that it has received a written notice from the staff of The NASDAQ Stock Market ("NASDAQ") informing the Company that trading of the Company's common stock would be suspended prior to the open of business on Thursday, January 21, 2010, and that NASDAQ would initiate procedures to delist the Company's common stock.
Cancer Research UK-funded scientists have discovered that linking a molecule which initiates antibody production,to a 'saboteur' molecule, triggers the immune system to selectively destroy faulty cells. These findings published in Blood, could potentially be used to selectively destroy tumour cells while ignoring healthy cells.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.
› Verified 2 days ago
Sav-on Pharmacy #3042 Type: Community/Retail Pharmacy Location: 6220 Us Hwy 287, Arlington, Texas 76017 Phone: (817) 478-1313 | |
Sav-on Pharmacy #4142 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 301 Sw Plaza Shopping Ctr, Arlington, Texas 76016 Phone: (817) 478-4238 | |
Savon Pharmacy #4163 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5950 S Cooper St, Arlington, Texas 76017 Phone: (817) 472-6458 | |
Anchor Medical Equipment, Inc. Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1030 W Pioneer Pkwy, Arlington, Texas 76013 Phone: (817) 461-6328 | |
Arlington Type: Prosthetic/Orthotic Supplier Location: 631 Matlock Centre Cir, Arlington, Texas 76015 Phone: (817) 200-6986 |